More than 200 studies and reports have been published regarding the use of
dexmedetomidine in infants and children. We reviewed the English literature to summarize …

Objective: To provide a general descriptive account of the end-organ effects of
dexmedetomidine and to provide an evidence-based review of the literature regarding its …

Dexmedetomidine is a potent and highly selective α2-adrenoreceptor agonist currently
utilized for continuous infusion for sedation/analgesia in the intensive care unit (ICU) …

Dexmedetomidine was introduced two decades ago as a sedative and supplement to
sedation in the intensive care unit for patients whose trachea was intubated. However, since …

Growing and consistent preclinical evidence, combined with early clinical epidemiological
observations, suggest potentially neurotoxic effects of commonly used anesthetic agents in …

Previous studies have shown that 1 μg. kg− 1 intranasal dexmedetomidine produces
significant sedation in children aged between 2 and 12 years. This investigation was …

Dexmedetomidine is being used off-label as an adjunctive agent for sedation and analgesia
in pediatric patients in the critical care unit and for sedation during non-invasive procedures …

Objectives: Although generally effective for sedation during noninvasive procedures,
dexmedetomidine as the sole agent has not been uniformly successful for invasive …

Importance of the field: Dexmedetomidine is an α2-adrenoceptor agonist with sedative,
anxiolytic and analgesic properties. It is used off-label in pediatric patients due to its efficacy …

Background Preoperative anxiety is common in pediatric patients. When dexmedetomidine
is used alone for sedation as premedication, children tend to awaken when separated from …